Skip to main content
CivicGate

S 5297
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

American Pharmaceutical Security Act

To require the Administrator of the Centers for Medicare & Medicaid Services to submit a report regarding the use of coverage and reimbursement authorities to protect the markets for active pharmaceutical ingredients and key staring materials.

Introduced Aug 6, 2026

Latest action (Aug 6, 2026) Read twice and referred to the Committee on Finance.

Referred to
Finance Committee
Policy area
Health
Issues
Healthcare

Summary
  • Requires the Administrator of the Centers for Medicare & Medicaid Services to submit a report to Congress within one year on using coverage and reimbursement authorities to protect domestic markets for active pharmaceutical ingredients and key starting materials.
  • Requires the report to include findings and policy recommendations on reducing U.S. dependence on foreign adversaries for pharmaceutical ingredients and materials.
  • Requires the report to identify existing data and information gaps related to the origin and ownership of active pharmaceutical ingredients and key starting materials.
  • Permits the report to include recommendations for price floor commitments to support domestic manufacturing of active pharmaceutical ingredients and key starting materials.
  • Permits the report to include recommendations to prioritize domestically manufactured active pharmaceutical ingredients and key starting materials over foreign-manufactured alternatives when domestic sources exist.

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)
1 cosponsor

Actions (2)
  1. Aug 6, 2026 Read twice and referred to the Committee on Finance. · senate
  2. Aug 6, 2026 Introduced in Senate

Text versions (1)
  • Introduced in Senate · Aug 6, 2026

Only one text version is on file, so there’s no earlier version to compare against yet.

Full text

IN THE SENATE OF THE UNITED STATES

August 6, 2026

Mr. Schiff (for himself and Mr. Scott of Florida) introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL

To require the Administrator of the Centers for Medicare & Medicaid Services to submit a report regarding the use of coverage and reimbursement authorities to protect the markets for active pharmaceutical ingredients and key staring materials.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “American Pharmaceutical Security Act”.

SEC. 2. REPORT ON MARKETS FOR API AND KEY STARTING MATERIALS.

(a) In General.—Not later than 1 year after the date of enactment of this Act, the Administrator of the Centers for Medicare & Medicaid Services (referred to in this section as the “Administrator”) shall submit to Congress a report on its findings and policy recommendations regarding the use of coverage and reimbursement authorities to protect the markets of the United States and its allies for active pharmaceutical ingredients and key starting materials and reduce direct and indirect dependence on foreign adversaries (as described in section 791.4 of title 15, Code of Federal Regulations (or any successor regulations)) for such ingredients and materials.

(b) Contents.—The report under subsection (a)—

(1) may include—

(A) recommendations for price floor commitments in support of domestic manufacturing of active pharmaceutical ingredients and key starting materials to protect investments in the domestic markets of such ingredients and materials against nonmarket practices and price manipulation; and

(B) recommendations that would prioritize domestically manufactured active pharmaceutical ingredients and key starting materials over foreign manufactured active pharmaceutical ingredients and key starting materials when a domestic source for the applicable ingredient or material exists; and

(2) shall identify any existing gaps in data and information related to the origin and ownership of active pharmaceutical ingredients and key starting materials that the Administrator would need to implement the recommendations included in the report. <all>

Comments

Comments

Loading comments…